The classic “GSK-3 hypothesis in AD” proposes that the over-activation of GSK-3β is closely associated with following pathological features including memory impairment, increased Aβ production, Tau phosphorylation and neuronal death (Balaraman et al., 2006). This evidence concerns the gene MAPT and Alzheimer disease.